Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
5.13
-0.37 (-6.73%)
Nov 18, 2026, 1:01 PM EST - Market open
Phathom Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Phathom Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $19.65. The average 1-year stock price forecast is 283.04% higher than the current stock price, while the lowest is $7.50 (+46.20%) and the highest is $29 (+465.30%).
Price Target: $19.65 (+283.04%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Phathom Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 8 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 12 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Reiterates $14 → $10 | Buy | Reiterates | $14 → $10 | +94.93% | Nov 18, 2026 |
| Leerink Partners | Leerink Partners | Hold Maintains $10 → $7.5 | Hold | Maintains | $10 → $7.5 | +46.20% | Nov 2, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $22 | Buy | Reiterates | $22 | +328.85% | Oct 30, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $26 | Buy | Reiterates | $26 | +406.82% | Oct 30, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Oct 23, 2026 |
Financial Forecast
Revenue This Year
315.03M
from 175.11M
Increased by 79.90%
Revenue Next Year
488.03M
from 315.03M
Increased by 54.92%
EPS This Year
-0.04
from -2.06
EPS Next Year
0.90
from -0.04
EPS and Forward PE are based on non-GAAP adjusted numbers.